Management of Major Bleeding with the Non-Vitamin K Oral Anticoagulants: the Role of Antidotes

Authors

  • Antonis S Manolis Third Department of Cardiology, Athens University School of Medicine, Athens, Greece
  • Helen Melita Onassis Cardiac Surgery Center, Athens

Keywords:

atrial fibrillation, anticoagulation, non-vitamin K anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, intracerebral hemorrhage, bleeding, antidotes, idarucizumab, andexanet, aripazine

Abstract

Over the recent years, new oral anticoagulant agents have been developed and entered the clinical arena, the direct or non-vitamin K oral anticoagulants (NOACs). Although more expensive, these agents have been proven as equivalent or superior to vitamin K antagonists in the treatment of non-valvular atrial fibrillation (AF) and venous thrombo-embolism with a lower incidence of intracerebral hemorrhage. Nevertheless, occurrence of major or life-threatening bleeding events is still quite possible. Thus, there is a major concern regarding the lack of a specific antidote and rapid reversal agent in such disastrous situations. Fortunately, the development of effective specific NOAC antidotes has recently made great advances, which are herein briefly reviewed.

Downloads

Download data is not yet available.

Downloads

Published

2016-03-04

Issue

Section

Editorial

How to Cite

Management of Major Bleeding with the Non-Vitamin K Oral Anticoagulants: the Role of Antidotes. (2016). Rhythmos, 11(1), 1-7. https://www.rhythmos.gr/index.php/Rhythmos/article/view/175

Similar Articles

1-10 of 106

You may also start an advanced similarity search for this article.